Medigen Vaccine Biologics Corporation (TPEX:6547)

Taiwan · Delayed Price · Currency is TWD

51.80

-0.40 (-0.77%)

Aug 19, 2026, 9:49 AM CST

Medigen Vaccine Biologics Financials Overview

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	573.85	613.17	605.64	389.62	365.04	3,281
Revenue Growth	-9.22%	1.24%	55.44%	6.73%	-88.87%	28413.03%
Gross Profit	361.55	364.67	396.42	230.22	-212.6	2,305
Operating Income	-181.12	-265.69	-145.67	-1,214	-1,536	963.73
Net Income	-166.77	-281.71	-80.47	-1,160	-1,475	1,410
Earnings Per Share	-0.53	-0.86	-0.24	-3.53	-4.56	4.39
EPS Growth	-	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	2,039	1,772	1,916	3,757	4,237	2,233
Total Debt	1,102	283.44	338.96	1,974	1,956	185.85
Net Cash (Debt)	936.8	1,489	1,577	1,783	2,281	2,047
Net Cash Growth	-33.09%	-5.58%	-11.56%	-21.85%	11.45%	32.50%
Net Cash Per Share	2.97	4.53	4.80	5.43	7.05	6.37

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-55.34	-49.09	40.75	-482.56	-1,214	579.89
Capital Expenditures	-162.21	-50.64	-34.3	-38.69	-139.17	-133.63
Free Cash Flow	-217.55	-99.72	6.46	-521.25	-1,353	446.26
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	63.00%	59.47%	65.45%	59.09%	-58.24%	70.25%
Operating Margin	-31.56%	-43.33%	-24.05%	-311.54%	-420.85%	29.37%
Pretax Margin	-29.06%	-45.94%	-13.29%	-297.68%	-403.95%	42.98%
Profit Margin	-29.06%	-45.94%	-13.29%	-297.68%	-403.95%	42.98%
FCF Margin	-37.91%	-16.26%	1.07%	-133.78%	-370.64%	13.60%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 19, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	-	-	-	-	-	45.14
Forward PE	56.74	218.70	39.19	-	-	-
P/FCF Ratio	-	-	1835.64	-	-	142.64
PS Ratio	29.90	20.24	19.57	59.12	62.42	19.40